GlassScriptPhysician profile
Don F Mills
NPI 1700809431
$2,857.88
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,470 · 2020: $247 · 2021: $19.23 · 2022: $59.67 · 2023: $61.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $814.30 | 2019-2022 | |
| Nevro Corp. | $644.01 | 2019 | |
| Daiichi Sankyo INC. | $250.35 | 2019 | |
| Collegium Pharmaceutical, INC. | $198.00 | 2019-2021 | |
| Bioventus LLC | $186.24 | 2019-2020 | |
| Horizon Therapeutics Plc | $140.78 | 2019 | |
| Stimwave Technologies Incorporated | $120.00 | 2019 | |
| Boston Scientific Corporation | $119.53 | 2019 | |
| Nalu Medical, INC. | $79.92 | 2022-2023 | Nalu Neurostimulation System |
| Sentynl Therapeutics, INC. | $65.39 | 2019 | |
| Kaleo, INC. | $60.97 | 2019 | |
| Scilex Pharmaceuticals INC. | $58.27 | 2019-2020 | |
| Pacira Therapeutics, INC. | $37.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.30 | 2019 | |
| Forte Bio-Pharma LLC | $23.09 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.18 | 2019 | |
| Assertio Therapeutics, INC. | $17.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.